Deep Value Stocks

ATUL has a strong recovered WHY: liquid epoxy resin capacity, product mix and improving group companies have already lifted results. Management has identified about ₹900 crore of sales from existing capacity, ₹600 crore from expansions and ₹300 crore initially from joint ventures. The recovery thesis fails if consolidated revenue growth drops below 5% for two quarters while EBITDA margin falls below 16%, or if the March 2027 power project slips without explanation.

This is Batch C's best operating setup: tile volume, pricing, adjacencies and cost savings are all helping, but control failures and forecasting errors keep it below Tier A. Two quarters below 5% tile volume growth or 17% OPM, or another control failure.

The wind EPC curve and order book are real, but repeated order delays, a silently tripled IPP capital plan, a lower FY27 growth floor and weak H2 cash flow make management credibility a material risk. The case fails if order inflow stalls, OCF turns negative, or the March FY27 execution spike does not arrive.

Demand, orders and the capacity ramp are real, but the stock depends on policy-protected 29-30% margins surviving a large industry capacity wave. The high-quality growth read fails if EBITDA margin stays below 27% for two quarters or the new 7 GW cell line fails to reach 70% use by Q4 FY27.

The earnings rise is real and broad-based, but the heavy capacity build must now turn into cash without another debt or equity step-up. The bullish read fails if FY27 PAT misses Rs 200 crore while OCF stays below Rs 200 crore and borrowing still rises.

Hotel demand, occupancy and fixed-cost leverage are lifting profit sharply, but delayed projects and a large reset in the room target stop this from being top-tier. The case fails if there is no meaningful FY27 room-opening progress, or if occupancy falls below 70% or EBITDA margin below 35% for two quarters.

Revenue and profit are compounding through more products and acquisitions, but cash conversion and changing margin guidance keep the curve below top quality. The read fails if FY27 OCF remains negative and Dice does not lift consolidated margin by the second half.

The earnings rise is real, but the next jump depends on a debt-funded cell plant whose timing and revenue targets have already been cut. The thesis fails if the cell line misses Q4 FY27 or cannot reach 60% utilization within two quarters while debt rises above ₹1,500 crore.

Premium fans, wires and cost savings are producing a real revenue and margin inflection, but gross-margin, working-capital and mix promises have not been consistently met. Revenue growth falls below 10% and EBITDA margin below 6% for two quarters.

This is a real bank turnaround: loan growth, funding mix and bad-loan cleanup all improved together, though some non-interest income and management targets need tighter checking. The turnaround fails if GNPA rises above 1.5%, slippage exceeds 0.5% annualized and NIM stays below 3.3%.

Gold loans and branch expansion are creating exceptional AUM and PAT growth, but rapid target changes, leadership changes and dilution require a lower credibility score. AUM growth falls below 25% while GNPA rises above 1.5%.

The margin rise is supported by premium mix and a larger order book, but the 30% growth target still requires delayed new products and project execution to arrive on time. The rerating case fails if WPC misses Q2 FY27, facade revenue misses Rs 40 crore and EBITDA margin drops below 18%.

Completed asset upgrades and higher room rates drove FY26, and management delivered its double-digit revenue promise. The next leg depends on RevPAR because there is no disclosed room-count growth, while Q1 FY27 consolidated PAT weakened and points to overseas-associate drag. The strong operating read fails if revenue growth drops below 5%, PBT margin falls below 15% or borrowings reverse above ₹150 crore.

Protection growth and cost control are lifting VNB, but repeated explanation changes on persistency, commissions and the FY27 growth stance prevent this from being called clean qualitative proof. The case fails if protection slows sharply and VNB growth falls below 10% for two quarters while persistency worsens.

The growth engine and order book are real, but the equity is now a heavily leveraged power-asset bet and management credibility has weakened. The case fails if IPP capacity misses 1.6 GW by FY27-end or OCF/PAT falls below 40% while debt keeps rising.

The core chemicals recovery is visible, but the new benzene plant is late and below plan, so much of the next growth step remains a forecast. The operating-leverage case fails if benzene cannot reach 70% use and term debt does not fall by at least Rs 150 crore.

AUM and profit are compounding near 30% with falling operating cost, but small-ticket stress and rising provisions make asset quality decisive. Two quarters above 1.6% credit cost with AUM growth below 20%.

New chemical capacity, richer materials mix and Fenesta growth can lift core earnings, but reported PAT is badly distorted by tax and asset-sale gains and management has changed project guidance often. Clean PAT fails to grow and ECH utilization does not improve by H2 FY27.

Sales, stores, old-gold exchange and diamond mix are all improving, but much of the FY26 margin spike came from gold-price gains and the business still consumes cash through inventory. Upgrade only if FY27 OCF turns positive and EBITDA margin stays at least 10% with flat-to-lower gold; downgrade if margin returns below 7.5% and PAT falls sharply.

The latest profit improvement is real because mix and cost discipline lifted margins even with lower sales, but TiO2 is impaired and management repeatedly predicted recoveries that did not arrive. The inflection fails if crop-protection margin falls below 15% before volume growth returns and pigment margin drops back below 8%.

The order book and factory ramp are real, but cash conversion worsened and management repeatedly changed growth and working-capital claims. The case fails if FY27 order conversion needs more debt while the cash cycle remains near 150 days.

The distribution network and MedTech mix are improving margins, but one cash-positive year must repeat before the curve becomes high quality. The upgrade fails if FY27 OCF/EBITDA is below 50% or consolidated margin does not approach 5%.

Campaign growth, pricing and staff productivity kept FY26 EBITDA margin near 30%, but revenue growth slowed to 6.3% and user traffic fell in Q4. Management met the margin promise, missed its growth promises and did not deliver the stated capital return while cash rose to ₹5,852 crore. The operating thesis fails if revenue growth falls below 5% with paid campaigns flat or declining; the value thesis fails if excess cash is still not returned and is instead deployed into a low-return related-party…

New chemical assets and captive power can add large profit, but commodity prices, other income and repeated capex/savings changes make the inflection cyclical and uncertain. New projects fail to add visible contribution by H2 FY27 while chemical margins fall.

Hotel pricing and upscale mix are real growth engines, but opening delays, changing cash-flow guidance and higher debt make the future curve less dependable than the demand story. The growth case weakens materially if same-store revenue growth falls below 9% and net-debt/EBITDA remains above 3x through FY28.

India's mix-led margin recovery is real, but Egypt and US conversion have slipped and management has repeatedly changed revenue and margin targets. The growth read fails if standalone margin falls below 15% for two quarters and Egypt still cannot hold 40% utilization.

Orders and margins are rising, but this remains a cash-hungry contractor with repeated numerical inconsistencies and reliance on debt for growth. The thesis fails if FY27 growth is funded by more debt without positive OCF or the PEB facility misses August 2026.

Productivity and pricing are improving, but headcount volatility, guidance cuts and other-income dependence make the PAT curve less durable than it looks. Headcount falls again and core EBITDA growth stays below 15%.

The Rajasthan and retail runway is visible, but slow collections, project delays and a one-off-heavy latest profit make the curve less powerful than it looks. The case fails if revenue growth stays below 10% for two more quarters or DSO rises above 160 days.

The recovery has begun and high-margin projects can lift profit, but leverage is high and management repeatedly cut targets or moved timelines. The recovery fails if FY27 aseptic volume misses 10 billion packs and net-debt/EBITDA remains above 4x after H1 commissioning.

The integrated workspace platform is growing, but repeated guidance cuts, dilution and debt make shareholder value much less certain than company-level growth. The case fails if share count does not freeze or FY27 seat/design growth misses the latest reduced targets.

Alkaline batteries and lighting are improving, but market-share reversal, delayed capacity and a large other-income boost mean the earnings curve is not yet clean. Alkaline share stays below 16% and core PAT does not grow without other income.

The operating engine is real: repeat customers, new defence and port projects, and a high-value project mix are lifting sales while margins remain near 30%. The shareholder engine is not yet proven because collections and repeated equity funding remain weak. The growth thesis fails if FY27 revenue misses ₹350 crore, OPM falls below 25%, or debtor days exceed 120; the cash-quality objection is disproved only if OCF/PAT exceeds 70%, debtor days are at most 90 and no shares…

The filings prove that vehicle sales, revenue and profit recovered. Fixed-cost absorption is our analytical inference from profit growing faster than revenue; management did not provide that explanation. The operating-leverage thesis fails if FY27 vehicle sales do not grow or PBT margin falls below 6%; the EV option remains unproven until unit sales and margins are disclosed.

FMCG mix and oil-palm integration can improve the business, but tax credits, commodity exposure and shifting segment guidance weaken the headline profit curve. The case fails if FMCG margin does not rise while reported PAT remains driven by tax credits rather than pre-tax profit.

Asset sales have genuinely cut debt and the order book supports a recovery, but execution, working capital and management's repeated target cuts keep this a fragile turnaround. The recovery fails if FY27 margin remains below 9.5%, working capital stays above 160 days after September and debt misses Rs 600 crore.

The operating case is becoming stronger through tower sharing, FTTH activation and acquisitions, but the shareholder case remains weak because the earlier curve was bought with a 141% share-count increase and deeply negative cash conversion. The C-grade is wrong if two more halves deliver OCF/PAT above 100%, no new equity, ROCE above 12%, and the acquisition increases recurring revenue without reducing EBITDA margin below 16%.

A large order book and coal ramp can revive revenue, but FY26 profit was mainly asset-sale income and guidance has been cut repeatedly. Core revenue misses 20% growth or debt fails to fall.

The BESS order gives revenue visibility, but one call and very poor historical cash conversion make this a high-risk execution bet. The case fails if the NTPC order does not produce cash or consolidated PAT margin remains at or below 7% in FY27.

The filing proves that profit recovery is turning into cash and debt repayment. It does not prove the commercial WHY because customer volumes, new programmes, utilisation and price changes are absent. Higher throughput and fixed-cost absorption are our inference, not management's explanation. The cash-led recovery fails if annual OCF turns negative, borrowings rise above the FY25 peak or quarterly revenue falls below ₹200 crore for two quarters.

Profit is rising despite a quarterly revenue decline, so margin and mix are doing the work. The filing does not explain why. Nine-month revenue still grew, but other income and the absence of cash-flow detail mean the quality of the latest profit step is not fully proven. The positive margin thesis fails if revenue stays negative year on year or other income exceeds 25% of PBT; it strengthens only if revenue re-accelerates above 10% while operating margin stays at least 15%.

US direct-to-consumer growth and store economics are promising, but weak cash conversion, falling group margin and repeated changes in management explanations keep this a low-quality curve. Drop the bullish case if US D2C misses Rs 375 crore and FY27 cash conversion remains below 50%.

This is a stable contracted-yield vehicle, not an explosive-growth company. A long RIL capacity reservation and a small tariff increase support cash distributions, but enterprise value is declining, debt is large and much of the latest distribution was return of capital. Do not treat this as a growth stock unless NDCF per unit rises sustainably from tariff or new capacity rather than only from capital return.

This is the strongest operating story in this seven-company gap set: margin rose despite lower FY26 revenue, the order book is large and unused wagon capacity gives room to grow. Reject the positive operating-leverage thesis if FY27 OCF remains negative while the order book keeps falling, or if installed capacity still does not move beyond 2,400 wagons.

Loan growth and bad-loan ratios are improving, but NIM keeps weakening and management has missed or moved several promises. NIM below 2.5% with slippages above Rs 300 crore.

The operating business is improving, but one call cannot prove that solar growth will finally convert into cash. The thesis fails if H1 FY27 OCF/PAT stays below 70% or OPM falls below 12%.

The current profit rise is mainly a fertilizer-cycle, subsidy-timing and other-income event. The only clearly verified structural lever is the Thal ammonia energy revamp, due July 2027; until then, the curve is not a new earnings regime. The negative read is wrong if two consecutive quarters have positive OCF, other income below 20% of PBT and OPM at least 7%, followed by verified 0.40 Gcal/MT energy savings after the Thal revamp.

The housing demand and premium-price story is real, but the PAT curve is not: it is dominated by one RMZ transaction gain and management missed every large FY26 operating target. The current bearish read is wrong only if FY27 OCF exceeds Rs 400 crore and two consecutive quarters show positive core operating margins without another asset-sale gain.

The company has a real specialty-product plan, but one call cannot repair the proven margin collapse, dilution and weak cash conversion. Upgrade only if OPM holds at least 12% for three halves, OCF/PAT exceeds 70%, and B2C reaches 30% without new dilution.

Loan growth and cheaper funding are expanding core interest profit, but the same fast growth has produced a visible credit-cost problem. This is a growth lender with an asset-quality repair option, not yet a clean deep-value compounding curve. The cautious thesis is wrong if GNPA stays below 2.5% for two quarters, NIM remains at least 3.5%, quarterly impairment falls below ₹150 crore and no new equity is issued.

Distribution expansion and product additions have delivered the sales targets, but the company still has not proved that low-margin electronics growth creates cash for shareholders. This is scale without cash quality. The C-grade is wrong if FY27 revenue grows above 25%, OPM stays at least 5.5%, OCF/PAT exceeds 70%, debt does not rise and no shares are issued.

Payment value is surging, but net revenue is almost flat because take rates are falling; strategy changes and cash-funded expansion make the curve unreliable. FY27 net revenue stays flat or FCF remains negative.

Revenue and EBITDA growth are real and supported by restarted factories and transmission orders. But the business has burned far more cash than its reported profit, debtor days are extreme, dilution funded the restart and the CEO resigned. The operating comeback is visible; shareholder-quality proof is not. Reject the turnaround if OCF does not become positive, debtor days do not fall below about 400 and the company issues more equity to fund execution.

The new Rajkot showroom gives a real revenue driver, but expansion outside Rajkot is only being evaluated. Cash conversion is poor, inventory is high and the Q4 margin collapse shows that FY26 profit cannot yet be treated as durable. Upgrade only if OCF/PAT exceeds 70%, inventory days fall and two quarters restore at least 15% OPM on sales growth rather than gold-price effects.

SEPC has the largest visible revenue runway in this group, with a claimed Rs 10,000 crore order book and a new Rs 673 crore SAIL order. Reject the turnaround if FY27 OCF stays negative, promoter ownership falls again, or the Avenir deal fails to increase pro-forma EPS after the 153 crore-share dilution.

The statutory result supports only a low-confidence cycle read, not a management WHY. The apparent staircase is cotton-yarn spread volatility: three loss quarters were followed by one 13% OPM quarter. No durable forward mechanism is scored. The cyclical-spike read is wrong only if OPM stays at least 10% for three consecutive quarters with revenue above ₹950 crore each quarter and borrowings fall below ₹900 crore.

The reported revenue jump is real but mainly acquisition-led. Dilution, Pepperfry's judgement-based deferred-tax asset, margin presentation that includes other income, and an unbridged FY30 revenue-potential slide make the curve low quality. Do not upgrade the curve unless two consecutive quarters show organic revenue growth, tax-normalised EPS growth, positive cash conversion and stable fully diluted shares; further material dilution or unbridged…

Profit grew and debt fell, but the operating reason is not proven. All four stores remain in Jaipur, cash conversion is weak and quarterly margin moved from an exceptional high to a sharp low without a sourced explanation. The positive case fails if the next two quarters do not hold 14%-16% OPM with OCF/PAT above 70% and stable promoter ownership.

The apparent profit staircase is not an operating recovery. FY26 revenue fell, textile margins remain thin and other income was larger than profit before tax. No numbered management plan explains why this should become a durable growth business. The negative view changes only if core OPM stays above 8% for three quarters, other income falls below 25% of PBT and borrowings stop rising.

The story is not investable evidence yet: only Rs 1,100 crore of the Rs 3,000 crore FY27 target is described as confirmed, while capex, margin and data-centre statements contradict each other. Do not upgrade unless signed orders bridge most of the Rs 1,900 crore gap, cash collection improves and the data-centre plan is reconciled in a filing.